Goldbug’s unique approach to solving the most vexing regulatory challenges has consistently produced unprecedented outcomes for our clients. I am proud of the value we bring to the diagnostic community and look forward to further enabling their success in advancing precision medicine.

Sheila D. Walcoff, J.D.

CEO and Founder

Recent News

Guardant Health Releases Results from ECLIPSE
Guardant Health Releases Results from ECLIPSE

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-announces-positive-results-from-pivotal-ECLIPSE-study-evaluating-a-blood-test-for-the-detection-of-colorectal-cancer/default.aspx Last week, Guardant Health released the results of...

FDA Explores Alternatives to CDx with New Pilot Program
FDA Explores Alternatives to CDx with New Pilot Program

https://www.fiercebiotech.com/medtech/fda-looks-bypass-cancer-drugs-companion-diagnostics-new-pilot-program-pazdur FDA had begun exploring ways around the one-drug-one-test limitations of companion diagnostics by looking further into the ‘minimal performance criteria’...